2024-00361. National Institute on Drug Abuse; Notice of Closed Meetings  

  • Start Preamble

    Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

    The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Translating Socioenvironmental Influences Start Printed Page 1580 on Neurocognitive Development and Addiction Risk (TranSINDA).

    Date: February 9, 2024.

    Time: 1:00 p.m. to 4:00 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

    Contact Person: Caitlin Elizabeth Angela Moyer, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443–4577, caitlin.moyer@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Chemical Countermeasures Research Program Initiative: Research on Counteracting the Deleterious Effects of Acute Opioid Exposure.

    Date: February 15, 2024.

    Time: 12:30 p.m. to 4:30 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

    Contact Person: Li Rebekah Feng, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–7245, rebekah.feng@nih.gov.

    Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Advancing Psychedelics Research for Treating Addiction.

    Date: February 21, 2024.

    Time: 11:00 a.m. to 5:00 p.m.

    Agenda: To review and evaluate grant applications.

    Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

    Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20852, (301) 480–1448, brian.wolff@nih.gov.

    (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

    Start Signature

    Dated: January 5, 2024.

    Lauren A. Fleck,

    Program Analyst, Office of Federal Advisory Committee Policy.

    End Signature End Preamble

    [FR Doc. 2024–00361 Filed 1–9–24; 8:45 am]

    BILLING CODE 4140–01–P

Document Information

Published:
01/10/2024
Department:
National Institutes of Health
Entry Type:
Notice
Document Number:
2024-00361
Dates:
February 9, 2024.
Pages:
1579-1580 (2 pages)
PDF File:
2024-00361.pdf